Drug intelligence / Profile preview

Alpharix

Development stage: Approved
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Alpharix is a prophylactic vaccine designed for the prevention of influenza in adults and children from 6 months of age. It contains inactivated influenza viruses, meaning they cannot cause the disease. The vaccine functions by stimulating the body's immune system to produce specific antibodies against the influenza viruses it is designed to target, thereby conferring protection against the flu. The vaccine targets influenza viruses in accordance with official recommendations.

Brand names: Fluviral
Other names: Alfarix

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on Alpharix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpharix.

Explore the full profile